| MA |
Report |
Net revenue |
IN-LINE |
pred ~$9.13B vs. cons $9.076B |
MEDIUM |
| MA |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$4.81 vs. cons $4.771 |
MEDIUM |
| MA |
Report |
Cross-border volume growth |
BEAT |
pred ~12.5% vs. cons 10.9% |
MEDIUM |
| MA |
Guide |
Q3 revenue growth (currency-neutral) |
UNCHANGED |
guide ~low-teens vs. 12.2% reported-revenue consensus; UNVERIFIED basis match |
LOW |
| MA |
Guide |
FY26 revenue growth (currency-neutral) |
UNCHANGED |
guide ~high end of low-double-digits vs. $37.129B reported-revenue consensus; UNVERIFIED basis match |
LOW |
| MA |
Guide |
Cross-border/travel recovery commentary |
UNCHANGED |
guide ~recovery consistent with prior Q2-contained disruption |
MEDIUM |
| MA |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| MA |
Return |
5-day cumulative residual |
-2.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — no FY estimate catalyst after a strong run |
LOW |